Zolgensma (Onasemnogene Abeparvovec-Xioi) Drug Interactions
Check all documented drug-to-drug interactions. Major, moderate, and minor interactions with descriptions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Zolgensma. Always confirm against the full prescribing information.
14 interactions
Adenovirus type 7 vaccine live
The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Onasemnogene abeparvovec.
Level 1 evidence
Anthrax vaccine
The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Onasemnogene abeparvovec.
Level 1 evidence
Bacillus calmette-guerin substrain tice live antigen
The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Onasemnogene abeparvovec.
Level 1 evidence
Chikungunya vaccine (live, attenuated)
The therapeutic efficacy of Chikungunya vaccine (live, attenuated) can be decreased when used in combination with Onasemnogene abeparvovec.
Level 1 evidence
Human adenovirus e serotype 4 strain cl-68578 antigen
The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Onasemnogene abeparvovec.
Level 1 evidence
Rubella virus vaccine
The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Onasemnogene abeparvovec.
Level 1 evidence
Smallpox (Vaccinia) Vaccine, Live
The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Onasemnogene abeparvovec.
Level 1 evidence
Typhoid Vaccine Live
The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Onasemnogene abeparvovec.
Level 1 evidence
Varicella zoster vaccine (live/attenuated)
The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Onasemnogene abeparvovec.
Level 1 evidence
Vibrio cholerae CVD 103-HgR strain live antigen
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Onasemnogene abeparvovec.
Level 1 evidence
Yellow fever vaccine
The therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Onasemnogene abeparvovec.
Level 1 evidence
Leflunomide
The risk or severity of liver damage can be increased when Onasemnogene abeparvovec is combined with Leflunomide.
Level 1 evidence
Enter your NPI to unlock 1 major interaction for Zolgensma
Zolgensma (Onasemnogene Abeparvovec-Xioi) has 14 documented drug interactions. Always review the full list with a pharmacist before co-prescribing.
Zolgensma (Onasemnogene Abeparvovec-Xioi) has 1 major, 11 moderate, and 2 minor documented interactions.
A therapy excluded from this list does not necessarily mean no interaction exists between that therapy and Zolgensma. Always confirm against the full prescribing information.